Condition: Alzheimer Disease · FTD · Young-onset Dementia · Sponsor: Ospedale Policlinico San Martino
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases. The study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.
This description comes directly from the study's public registry record.
Paola Mandich, MD, PhD · +39 3473051001 · paola.mandich@unige.it
Vittorio Bocchini, Dr · vittorio.bocchini@hsanmartino.it
Always discuss trial participation with your own doctor first.
| Ospedale Policlinico San Martino | Genoa, Genoa, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07235111